Biostem Technologies Inc
OTC:BSEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biostem Technologies Inc
Additional Paid In Capital
Biostem Technologies Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biostem Technologies Inc
OTC:BSEM
|
Additional Paid In Capital
$60.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Additional Paid In Capital
$46.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
41%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Additional Paid In Capital
$94.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Additional Paid In Capital
$45B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
Biostem Technologies Inc
Glance View
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
See Also
What is Biostem Technologies Inc's Additional Paid In Capital?
Additional Paid In Capital
60.3m
USD
Based on the financial report for Dec 31, 2025, Biostem Technologies Inc's Additional Paid In Capital amounts to 60.3m USD.
What is Biostem Technologies Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
36%
Over the last year, the Additional Paid In Capital growth was 10%. The average annual Additional Paid In Capital growth rates for Biostem Technologies Inc have been 36% over the past three years .
